Altimmune, Inc.

NASDAQ:ALT

Biotechnology

Healthcare
$1.53 +3.09%

+$0.08 today

Market cap
$297.72M
Beta
0.23
P/E (TTM)
-3.7
EPS (TTM)
-$0.73
52W Low $2.56High $7.73

Volume 4.25M

Average 3.81M

ALT EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Altimmune, Inc.NASDAQ: ALT

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$21.47M, compared with -$20.23M a year earlier. Trailing-twelve-month EBITDA was -$88.27M.

Context

  • EBITDA amounted to 212258.5% of revenue in FY2025, down 261801.5 pp from a year earlier.
  • EBITDA grew in size in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 6 analysts of -$53.68M (+38.3%) for the fiscal year ending Dec 2026, a step up from the +8.2% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$21.47M+18.8% QoQ
Last fiscal yearDec 2025
-$87.03M+8.2% YoY
LTMMar 2026
-$88.27M+2.7% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-6.2%-25.0%-18.8 pp
1 year+8.2%+38.3%+30.1 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(87.03M) USD
Year-over-year change
+8.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How ALT compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +2.7% is the 7th highest of 9, against a peer median of +35.5%.
  • EBITDA amounts to 245200.0% of revenue for ALT, versus a peer median of 84.0%.
ALT Competitors
EBITDA for ALT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ABUSArbutus Biopharma CorporationLTM Mar 2026$160.85M USD+305.5%—84.0%
ASMBAssembly Biosciences, Inc.LTM Mar 2026-$6.26M USD+84.1%—8.8%
INDPIndaptus Therapeutics, Inc.LTM Mar 2026-$18.86M USD-19.7%——
BMEABiomea Fusion, Inc.LTM Mar 2026-$46.12M USD+63.6%——
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026-$46.56M USD+46.6%—67.3%
ALTAltimmune, Inc.LTM Mar 2026-$88.27M USD+2.7%—245200.0%
IVAInventiva S.A.FY2025-€128.15M EUR+23.0%—2858.6%
GPCRStructure Therapeutics Inc.LTM Jun 2026-$212.44M USD-19.8%——
VIRVir Biotechnology, Inc.LTM Mar 2026-$438.52M USD+24.4%—669.6%
Peer median (excluding ALT) —+35.5%—84.0%

Competitors are the stored peer set for ALT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.41M(68K)426K20K41K
Cost of Revenue00000
Gross Profit4.41M(68K)426K20K41K
Gross Margin100.0%100.0%100.0%100.0%100.0%
Research & Development74.54M70.54M65.8M82.23M66.43M
Selling, General & Admin15.41M17.13M18.14M20.97M28.1M
Operating Expenses101.32M87.67M96.36M103.19M94.53M
Depreciation & Amortization551K493K477K238K112K
EBITDA(96.53M)(84.41M)(87.94M)(94.81M)(87.03M)
EBITDA Margin-2189.0%124130.9%-20642.0%-474060.0%-212258.5%
Operating Income(96.91M)(87.74M)(95.93M)(103.17M)(94.49M)
Operating Margin-2197.6%129029.4%-22518.5%-515860.0%-230461.0%
Interest Income203K2.87M7.35M8.07M7.54M
Interest Expense5K8K35K9K1.64M
Other Income / Expenses(176K)2.83M7.48M8.11M5.72M
Income Before Tax(97.09M)(84.91M)(88.45M)(95.06M)(88.77M)
Pre-Tax Margin-2201.6%124867.6%-20762.2%-475295.0%-216522.0%
Income Tax Expense0(197K)00(681K)
Net Income(97.09M)(84.71M)(88.45M)(95.06M)(88.09M)
Net Margin-2201.6%124577.9%-20762.2%-475295.0%-214861.0%
EPS (Basic)(2.35)(1.81)(1.66)(1.34)(1.00)
EPS (Diluted)(2.35)(1.81)(1.66)(1.34)(1.00)
Weighted Avg Shares41.28M46.93M53.25M71M88.1M
Weighted Avg Shares (Diluted)41.28M46.93M53.25M71M88.1M

Altimmune, Inc.

NASDAQ:ALT

Intrinsic Alpha fair value

Locked

Current Price

$1.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.